肝癌患者血清中lncRNA MIAT的表达及临床意义

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (2): 40-43.

肝癌患者血清中lncRNA MIAT的表达及临床意义

阳航^*, 黄裕红, 伍玉南

湖南中医药大学附属一医院肝病科,湖南长沙 410007

收稿日期:2020-03-20 出版日期:2020-06-30 发布日期:2020-07-23
通讯作者: ^* 阳航 E-mail: pingapp@163.com
作者简介:阳航,副主任医师,湖南中医药大学附属一医院肝病科。

Expression of lncRNA MIAT in serum of patients with hepatocellular carcinoma and its clinical significance

Yang Hang^*, Huang Yuhong, Wu Yunan

Department of Hepatology, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, Hunan, China

Received:2020-03-20 Online:2020-06-30 Published:2020-07-23

摘要/Abstract

摘要： 目的: 检测肝细胞癌（hepatocellular carcinoma,HCC）患者血清中长链非编码RNA (long non-coding RNA,lncRNA) 心肌梗死相关转录本(myocardial infraction association transcript,MIAT)的表达,并探讨其临床意义。方法: qRT-PCR法检测血清MIAT表达;ROC曲线分析其诊断HCC的价值;并研究MIAT表达与疾病进展及预后的关系。结果: MIAT在HCC患者血清中高表达,ROC曲线表明其表达可作为诊断HCC的血清标志物;与临床因素对比后发现MIAT表达与肿瘤数目、TNM分期和BCLC分期密切相关;对血清MIAT水平随访后发现其表达在肝癌肝切除术后降低,并在HCC复发时升高。结论: 血清MIAT水平可作为诊断HCC的生物学标志物,其在评估HCC的恶性进展、手术疗效以及预测肿瘤复发方面具有潜在临床应用价值。

关键词: 长链非编码RNA, 心肌梗死相关转录本, 血清, 生物标志物

Abstract: Objective: To detect the expression of Long non-coding RNA (lncRNA) myocardial infraction association transcript (MIAT) in serum of patients with hepatocellular carcinoma (HCC) and to explore its clinical significance.Methods: The expression of MIAT in serum of HCC patients was detected by qRT-PCR assay. The value of MIAT expression in the diagnosis of HCC was assessed by ROC curve, and the relationship between MIAT expression with HCC disease progression and prognosis was analyzed.Results: MIAT was highly expressed in serum of HCC patients, and ROC curve showed that MIAT expression could be used as a serum marker for diagnosis of HCC. MIAT expression was closely related to tumor number, TNM stage and BCLC stage. MIAT expression decreased after resection of HCC and increased when HCC recurred.Conclusion: Serum MIAT level can be used as a biomarker for the diagnosis of HCC. It has potential clinical value in evaluating the malignant progression and surgical efficacy of HCC as well as predicting recurrence of HCC.

Key words: Long non-coding RNA, Myocardial infraction association transcript, Serum, Biomarkers

阳航, 黄裕红, 伍玉南. 肝癌患者血清中lncRNA MIAT的表达及临床意义[J]. 肝癌电子杂志, 2020, 7(2): 40-43.

Yang Hang, Huang Yuhong, Wu Yunan. Expression of lncRNA MIAT in serum of patients with hepatocellular carcinoma and its clinical significance[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 40-43.

参考文献

[1] REN W, QI XS, JIA J, et al.Hepatocellular carcinoma[J]. Lancet, 2012, 380(9840):469.
[2] LU LC, CHENG AL, POON RTP.Recent advances in the prevention of hepatocellular carcinoma recurrence[J]. Semin Liver Dis, 2014, 34(4):427-434.
[3] Zucman-Rossi J, Villanueva A, Nault JC, et al.Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149(5): 1226-1239.
[4] SUN Y, MA L.New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis. Cancers (Basel), 2019, 11(2): E216.
[5] RAFIEE A, RIAZI-RAD F, HAVASKARY M, et al.Long noncoding RNAs: regulation, function and cancer[J]. Biotechnol Genet Eng Rev, 2018, 34(2):153-180.
[6] ZHENG C, HAO H, CHEN L, et al.Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Transl Oncol, 2017, 19(8): 961-968.
[7] LEE YR, KIM G, TAK WY, et al.Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma[J]. Int J Cancer, 2019, 144(6):1444-1452.
[8] XIANG Y, HUANG YG, SUN H, et al.Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation[J]. Biomed Pharmacother, 2019, 109:1630-1639.
[9] HUANG XL, GAO Y, QIN JJ, et al.lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 314(5):G559-G565.
[10] OHNISHI Y, TANAKA T, YAMADA R, et al.Identification of 187 single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic heart disease in the Japanese population[J]. Hum Genet, 2000, 106(3):288-292.
[11] ISHII N, OZAKI K, SATO H, et al.Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction[J]. J Hum Genet, 2006, 51(12):1087-1099.
[12] SUN C, HUANG LN, LI ZL, et al.Long non-coding RNA MIAT in development and disease: a new player in an old game[J]. J Biomed Sci, 2018, 25(1):23.
[13] WANG RJ, ZHAO LN, Ji LL et al. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212[J]. Biomed Pharmacother, 2019, 118:109298.
[14] LIN D, XU HP, LIN JH, et al.Long non-coding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-1246[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13):5795-5801.
[15] BOUNTALI A, TONGE DP, MOURTADA-MAARABOUNI M.RNA sequencing reveals a key role for the long non-coding RNA MIAT in regulating neuroblastoma and glioblastoma cell fate[J]. Int J Biol Macromol, 2019, 130:878-891.
[16] TAN J, LIU SZ, JIANG Q, et al.LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease[J]. Cardiol Res Pract, 2019, 2019:6280194.
[17] XIANG Y, HUANG YG, SUN H, et al.Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation[J]. Biomed Pharmacother, 2019, 109:1630-1639.